P. Falciparum Resistance to Artemisinin in Vietnam
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02604966|
Recruitment Status : Unknown
Verified October 2015 by National Institute of Malariology, Parasitology and Entomology, Vietnam.
Recruitment status was: Recruiting
First Posted : November 16, 2015
Last Update Posted : December 21, 2015
At the end of 2012, the Institute of Tropical Medicine in collaboration with National Institute of Malariology Parasitology and Entomology (NIMPE) conducted a study in Quang Nam province, central Vietnam, to assess the efficacy of the national DHA-PPQ regimen for the treatment of uncomplicated P. falciparum malaria infections, both in adults and in children. Results showed that about 30% of the study participants were parasitaemic at day 3. Parasite clearance rate was estimated at 6.2h, which was comparable to figures from Pailin, Cambodia, where artemisinin resistance were previously reported . However, results from this study have to be interpreted bearing in mind that: (i) the age-based drug dosing scheme used has been criticized as insufficient to clear parasites and (ii) DHA-PPQ drugs used (Artecan™), Vietnam, are not produced under Good Manufacturing Practices (GMPs). However, those results prompted the NMCP and WHO to declare Quang Nam, Binh Phuoc, Dak Nong, and Gia Lai provinces as a "Tier I area" (credible evidence of artemisinin resistance) in May 2013. By end of 2014 a fifth province, Khanh Hoa, was declared Tier I (Dr Hong, Personal Communication). Except for the south-eastern province of Binh Phuoc, artemisinin resistance has never been confirmed with an artemisinin based monotherapy in Central Vietnam.
Therefore, in order to confirm artemisinin resistance in Central Vietnam , a study with oral artemisinin-based monotherapy, using WHO prequalified AS and DHA-PPQ and recommended dosing scheme of 4mg/kg/day for AS and DHA, is needed. In the arm where study participants are treated with 3 days of AS monotherapy, treatment will be followed by an additional 3-day course of DHA-PPQ to effectively clear all parasites.
The aim of the present study is to confirm artemisinin resistance in Central Vietnam by assessing P. falciparum clearance time and rate after AS monotherapy (WHO recommended dosage). The investigators will conduct a two-arm open label, randomized study, with one arm receiving AS monotherapy for 3 days + 3-day of DHA-PPQ, and a second arm receiving 3 days of DHA-PPQ.
|Condition or disease||Intervention/treatment||Phase|
|Drug Resistant Malaria Due to Plasmodium Falciparum||Drug: Artesunate (AS) group Drug: DHA - PPQ group||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||120 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Efficacy of Artesunate Monotherapy and Dihydroartemisinin - Piperaquine in Patients With Uncomplicated Falciparum Malaria in Central Vietnam|
|Study Start Date :||April 2015|
|Estimated Primary Completion Date :||September 2016|
|Estimated Study Completion Date :||December 2016|
Experimental: Artesunate (AS) group
P. falciparum infected patients randomly allocated to this arm will be treated with AS (50mg/tablet) 4 mg/kg body weight once daily for three days followed by DHA-PPQ (40mg of DHA +320mg of PPQ/tablet) once daily for three days.
Drug: Artesunate (AS) group
Oral treatment with AS at 4mg/kg/day for 3 days followed by three days of DHA - PPQ in order to insure total parasite clearance. Randomization is done by blocks of ten.
Other Name: AS group
Active Comparator: DHA - PPQ group
P. falciparum infected patients randomly allocated to this arm will be treated with the combination DHA-PPQ (40mg of DHA +320mg of PPQ/tablet) once daily for three days.
Drug: DHA - PPQ group
Oral treatment with 3-day course of DHA - PPQ. Randomization is done by blocks of ten.
- Median parasite clearance time after treatment with Artesunate or with DHA - PIP [ Time Frame: From time of first treatment dose (day0 hh-mm) until day and time of parasite clearance (=two consecutive blood samples are found negative for parasites) assessed up day 42 ]Median parasite clearance time (total hours) in both arms (by light microscopy (LM) and quantitative real time PCR (qPCR)) will be computed using the 12-hourly parasite density measurements from day0 till parasite clearance. Parasite clearance time (in hours) will be computed using the Parasite Clearance Estimator tool available online (http://www.wwarn.org/toolkit/data-management/parasite-clearance-estimator).
- Number of patients with Adequate Clinical and Parasitological Response (ACPR) to DHA-PPQ for the treatment for uncomplicated P falciparum malaria infections in central Vietnam. [ Time Frame: From day0 to day 42 ]This outcome is measured at day 28 and 42 of follow-up. Treatment outcomes such as ACPR, early or late clinical failures are defined following WHO guidelines;
- Ex vivo susceptibility of P. falciparum isolates to AS, DHA , PPQ and CQ (Mean IC50 and IC90) [ Time Frame: At day0 and day of recurrence of P.falciparum parasitemia after initial clearance assessed up to day 42 ]Individual and mean IC50 and IC90 values will be computed for each drug using the IVART tool available online (http://www.wwarn.org/tools-resources/toolkit/analyse/ivart)
- Number of patients carrying asexual and sexual parasites during 42 days follow up [ Time Frame: From day0 to day 42 ]asexual and sexual parasite forms will be detected by quantitative qPCR and reverse transcription real time PCR (rtPCR), respectively. This outcome will be measured for each sampling time point.
- Number of patients with parasites carrying molecular markers of Plasmodium falciparum resistance to artemisinins. [ Time Frame: From day 0 to day42 ]All parasites at day0, and day3 for patients with delayed clearance, will be genotyped for molecular markers of artemisinin resistance (K13 mutations) following a published protocol.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02604966
|Contact: Phuc Bui, MD, PhD||+84 913522 email@example.com|
|Contact: Duong Tran, MD, PhDfirstname.lastname@example.org|
|Chu R Cam commune||Recruiting|
|Pleiku, Gialai, Vietnam|
|Contact: Phuc Bui, MD, PhD +84913522874 email@example.com|
|Contact: Hong Nguyen, MD +841668188919 firstname.lastname@example.org|
|Sub-Investigator: Annette Erhart, MD, PhD|
|Sub-Investigator: Edu Rovira - Vallbona, PhD|
|Principal Investigator:||Duong Tran, MD, PhD||National Institute of Malariology, Parasitology and Entomology, Hanoi, Vietnam|
|Principal Investigator:||Anna Rosanas-Urgell, MD, PhD||Institute of Tropical Medicine, Antwerp, Belgium|